As part of the NICE’s Single Technology Appraisal process, this assessment critically reviewed the evidence for the clinical and cost-effectiveness of secukinumab for treating moderate to severe plaque psoriasis. The evidence was submitted by Novartis, the company that manufactures secukinumab (Cosentyx) and consisted of four phase III RCTs comparing secukinumab with placebo and a dose-response trial. The current NICE guidance, based on the results of this appraisal, recommends secukinumab as an option for treating people with plaque psoriasis if (1) the disease is severe, as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10; (ii) the disease has failed to respond to standard systemic therapies, for example, ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or these treatments are contraindicated or the person cannot tolerate them; (iii) the company provides secukinumab with the discount agreed in the patient access scheme.
Miriam Brazzelli: email@example.com
For further information: